Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Osteoporosis-Pipeline Review, H1 2015

Osteoporosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Osteoporosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Osteoporosis-Pipeline Review, H1 2015', provides an overview of the Osteoporosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Osteoporosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Osteoporosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Osteoporosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Osteoporosis Overview 11

Therapeutics Development 12

Pipeline Products for Osteoporosis-Overview 12

Pipeline Products for Osteoporosis-Comparative Analysis 13

Osteoporosis-Therapeutics under Development by Companies 14

Osteoporosis-Therapeutics under Investigation by Universities/Institutes 20

Osteoporosis-Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Osteoporosis-Products under Development by Companies 26

Osteoporosis-Products under Investigation by Universities/Institutes 33

Osteoporosis-Companies Involved in Therapeutics Development 35

Abiogen Pharma S.p.A. 35

Ablynx NV 36

Alethia Biotherapeutics Inc. 37

Alize Pharma SAS 38

Alkem Laboratories Ltd. 39

Amgen Inc. 40

Amura Holdings Limited 41

Arcarios BV 42

Astellas Pharma Inc. 43

Bone Medical Limited 44

Bone Therapeutics SA 45

Caladrius Biosciences, Inc. 46

Chronos Therapeutics Limited 47

Chugai Pharmaceutical Co., Ltd. 48

Corium International, Inc. 49

Critical Pharmaceuticals Limited 50

Daiichi Sankyo Company, Limited 51

ElexoPharm GmbH 52

Eli Lilly and Company 53

EndoCeutics, Inc. 54

Ensoltek Co., Ltd. 55

Enzo Biochem, Inc. 56

F. Hoffmann-La Roche Ltd. 57

Galapagos NV 58

Glide Pharmaceutical Technologies Limited 59

Hanmi Pharmaceuticals, Co. Ltd. 60

Haoma Medica Ltd. 61

IMMD Inc. 62

Immunovo BV 63

Inbiopro Solutions Pvt. Ltd. 64

Kaken Pharmaceutical Co., Ltd. 65

Kolltan Pharmaceuticals, Inc. 66

Lead Discovery Center GmbH 67

Lupin Limited 68

Medivir AB 69

Merck & Co., Inc. 70

Merrion Pharmaceuticals Plc 71

Novartis AG 72

Omeros Corporation 73

Oncobiologics, Inc. 74

Oscotec Inc. 75

Osteologix Holdings Plc 76

Pantarhei Bioscience BV 77

Paras Biopharmaceuticals Finland Oy 78

Pfizer Inc. 79

PhytoHealth Corporation 80

PolyNovo Limited 81

R-Pharm 82

Radius Health, Inc. 83

Richter Gedeon Nyrt. 84

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 85

Shin Poong Pharm.Co., Ltd. 86

STELIS Biopharma Pvt. Ltd. 87

Sumitomo Dainippon Pharma Co., Ltd. 88

Takeda Pharmaceutical Company Limited 89

TAmiRNA GmbH 90

TSRL, Inc. 91

Uni-Bio Science Group Ltd. 92

Unigene Laboratories, Inc. 93

Ventria Bioscience 94

Wroclawskie Centrum Badan EIT+ Sp. z o.o. 95

Zydus Cadila Healthcare Limited 96

Osteoporosis-Therapeutics Assessment 97

Assessment by Monotherapy Products 97

Assessment by Combination Products 98

Assessment by Target 99

Assessment by Mechanism of Action 102

Assessment by Route of Administration 105

Assessment by Molecule Type 107

Drug Profiles 109

(aceclofenac + eperisone)-Drug Profile 109

AB-25E9-Drug Profile 110

abaloparatide-Drug Profile 111

alendronate sodium-Drug Profile 114

alendronate sodium-Drug Profile 116

alendronate sodium-Drug Profile 117

ALX-0141-Drug Profile 118

AM-3701-Drug Profile 119

AOD-9604-Drug Profile 120

ARC-205-Drug Profile 122

AS-2690168-Drug Profile 123

astrogorgiadiol-Drug Profile 124

bazedoxifene acetate-Drug Profile 125

Biosimilar for Osteoporosis-Drug Profile 127

blosozumab-Drug Profile 128

BN-005-Drug Profile 129

BN-008-Drug Profile 130

calcitonin-Drug Profile 131

CDR-914K058-Drug Profile 133

CDRI-99/373-Drug Profile 134

CH-5036249-Drug Profile 135

denosumab-Drug Profile 136

denosumab biosimilar-Drug Profile 139

denosumab biosimilar-Drug Profile 140

Drug to Inhibit miR-31 for Osteoporosis-Drug Profile 141

Drug to Target miR-002 for Osteoporosis-Drug Profile 142

Drugs for Osteoporosis-Drug Profile 143

Drugs for Postmenopausal Osteoporosis-Drug Profile 144

Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders-Drug Profile 145

DS-1501-Drug Profile 146

esterol-Drug Profile 147

Eu-232-Drug Profile 149

genipin-Drug Profile 150

I-HBD1-Drug Profile 151

ibandronate sodium-Drug Profile 152

IBPB-008IG-Drug Profile 154

IMD-2560-Drug Profile 155

IPS-02 Series-Drug Profile 156

K-671-Drug Profile 157

MAb-7-Drug Profile 158

MIV-711-Drug Profile 159

Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis-Drug Profile 160

Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis-Drug Profile 161

MOR-106-Drug Profile 162

NBS-101-Drug Profile 163

NEP-28-Drug Profile 165

neridronic acid-Drug Profile 166

OCT-1547-Drug Profile 167

odanacatib-Drug Profile 168

ODS-656-Drug Profile 170

Oratonin-Drug Profile 171

OXY-149-Drug Profile 172

Peniel-3000-Drug Profile 173

PHN-031-Drug Profile 174

poncirin-Drug Profile 175

prasterone + acolbifene hydrochloride-Drug Profile 176

PREOB-Drug Profile 177

Protein 1 for Rheumatoid Arthritis and Osteoporosis-Drug Profile 178

Protein 2 for Rheumatoid Arthritis and Osteoporosis-Drug Profile 179

Protein 3 for Rheumatoid Arthritis and Osteoporosis-Drug Profile 180

Proteins to Inhibit RANKL for Breast Cancer and Osteoporosis-Drug Profile 181

PTH-CBD-Drug Profile 182

RDC-5-Drug Profile 184

Recombinant Protein for Osteoporosis-Drug Profile 186

Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis-Drug Profile 187

Recombinant Protein to Inhibit Serine Protease for Bone Disorders and Osteoporosis-Drug Profile 188

romosozumab-Drug Profile 189

RPH-203-Drug Profile 191

S-007-1500-Drug Profile 192

S-101479-Drug Profile 193

S-49288-Drug Profile 194

SBL-001-Drug Profile 195

Small Molecule to Agonize LRP for Osteoporosis-Drug Profile 196

Small Molecule to Agonize PTH-1R for Osteoporosis-Drug Profile 197

Small Molecule to Inhibit Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis-Drug Profile 198

Small Molecule to Modulate Estrogen Receptor for Breast Cancer and Osteoporosis-Drug Profile 199

Small Molecule to Target LGR4 for Cancer and Osteoporosis-Drug Profile 200

Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders-Drug Profile 201

Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders-Drug Profile 202

Small Molecules for Osteopenia and Osteoporosis-Drug Profile 203

Small Molecules for Osteoporosis-Drug Profile 204

Small Molecules for Osteoporosis-Drug Profile 205

Small Molecules for Primary Juvenile Osteoporosis-Drug Profile 207

Small Molecules to Activate CB2 for Osteoporosis-Drug Profile 208

Small Molecules to Agonize Glucocorticoid Receptor for Osteoporosis-Drug Profile 209

Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis-Drug Profile 210

Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis-Drug Profile 211

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology-Drug Profile 212

Small Molecules to Inhibit Src Tyrosine Kinase for Oncology, Cardiovascular and Metabolic Disorders-Drug Profile 213

Small Molecules to Target Androgen Receptor for Osteoporosis-Drug Profile 214

Sodium Quinate-Drug Profile 215

SP-35454-Drug Profile 216

SR-2595-Drug Profile 217

Stem Cell Therapy for Osteoporosis and Periodontitis-Drug Profile 218

Synthetic Peptide for Osteoporosis and Bone Fracture-Drug Profile 219

TAK-075-Drug Profile 220

teriparatide-Drug Profile 221

teriparatide-Drug Profile 223

teriparatide-Drug Profile 224

teriparatide-Drug Profile 226

teriparatide-Drug Profile 227

teriparatide acetate-Drug Profile 228

teriparatide biosimilar-Drug Profile 229

teriparatide biosimilar-Drug Profile 230

Vaccine to Target Sclerostin for Osteoporosis-Drug Profile 231

VEN-130-Drug Profile 232

VS-105-Drug Profile 233

VS-401-Drug Profile 234

VS-411-Drug Profile 235

zoledronic acid-Drug Profile 236

Osteoporosis-Recent Pipeline Updates 238

Osteoporosis-Dormant Projects 261

Osteoporosis-Discontinued Products 270

Osteoporosis-Product Development Milestones 272

Featured News & Press Releases 272

Appendix 285

Methodology 285

Coverage 285

Secondary Research 285

Primary Research 285

Expert Panel Validation 285

Contact Us 285

Disclaimer 286

List of Tables

Number of Products under Development for Osteoporosis, H1 2015 20

Number of Products under Development for Osteoporosis-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 23

Number of Products under Development by Companies, H1 2015 (Contd..1) 24

Number of Products under Development by Companies, H1 2015 (Contd..2) 25

Number of Products under Development by Companies, H1 2015 (Contd..3) 26

Number of Products under Development by Companies, H1 2015 (Contd..4) 27

Number of Products under Investigation by Universities/Institutes, H1 2015 29

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Development, H1 2015 32

Comparative Analysis by Unknown Stage Development, H1 2015 33

Products under Development by Companies, H1 2015 34

Products under Development by Companies, H1 2015 (Contd..1) 35

Products under Development by Companies, H1 2015 (Contd..2) 36

Products under Development by Companies, H1 2015 (Contd..3) 37

Products under Development by Companies, H1 2015 (Contd..4) 38

Products under Development by Companies, H1 2015 (Contd..5) 39

Products under Development by Companies, H1 2015 (Contd..6) 40

Products under Investigation by Universities/Institutes, H1 2015 41

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 42

Osteoporosis-Pipeline by Abiogen Pharma S.p.A., H1 2015 43

Osteoporosis-Pipeline by Ablynx NV, H1 2015 44

Osteoporosis-Pipeline by Alethia Biotherapeutics Inc., H1 2015 45

Osteoporosis-Pipeline by Alize Pharma SAS, H1 2015 46

Osteoporosis-Pipeline by Alkem Laboratories Ltd., H1 2015 47

Osteoporosis-Pipeline by Amgen Inc., H1 2015 48

Osteoporosis-Pipeline by Amura Holdings Limited, H1 2015 49

Osteoporosis-Pipeline by Arcarios BV, H1 2015 50

Osteoporosis-Pipeline by Astellas Pharma Inc., H1 2015 51

Osteoporosis-Pipeline by Bone Medical Limited, H1 2015 52

Osteoporosis-Pipeline by Bone Therapeutics SA, H1 2015 53

Osteoporosis-Pipeline by Caladrius Biosciences, Inc. , H1 2015 54

Osteoporosis-Pipeline by Chronos Therapeutics Limited, H1 2015 55

Osteoporosis-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 56

Osteoporosis-Pipeline by Corium International, Inc., H1 2015 57

Osteoporosis-Pipeline by Critical Pharmaceuticals Limited, H1 2015 58

Osteoporosis-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 59

Osteoporosis-Pipeline by ElexoPharm GmbH, H1 2015 60

Osteoporosis-Pipeline by Eli Lilly and Company, H1 2015 61

Osteoporosis-Pipeline by EndoCeutics, Inc., H1 2015 62

Osteoporosis-Pipeline by Ensoltek Co., Ltd., H1 2015 63

Osteoporosis-Pipeline by Enzo Biochem, Inc., H1 2015 64

Osteoporosis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 65

Osteoporosis-Pipeline by Galapagos NV, H1 2015 66

Osteoporosis-Pipeline by Glide Pharmaceutical Technologies Limited, H1 2015 67

Osteoporosis-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 68

Osteoporosis-Pipeline by Haoma Medica Ltd., H1 2015 69

Osteoporosis-Pipeline by IMMD Inc., H1 2015 70

Osteoporosis-Pipeline by Immunovo BV, H1 2015 71

Osteoporosis-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 72

Osteoporosis-Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015 73

Osteoporosis-Pipeline by Kolltan Pharmaceuticals, Inc., H1 2015 74

Osteoporosis-Pipeline by Lead Discovery Center GmbH, H1 2015 75

Osteoporosis-Pipeline by Lupin Limited, H1 2015 76

Osteoporosis-Pipeline by Medivir AB, H1 2015 77

Osteoporosis-Pipeline by Merck & Co., Inc., H1 2015 78

Osteoporosis-Pipeline by Merrion Pharmaceuticals Plc, H1 2015 79

Osteoporosis-Pipeline by Novartis AG, H1 2015 80

Osteoporosis-Pipeline by Omeros Corporation, H1 2015 81

Osteoporosis-Pipeline by Oncobiologics, Inc., H1 2015 82

Osteoporosis-Pipeline by Oscotec Inc., H1 2015 83

Osteoporosis-Pipeline by Osteologix Holdings Plc, H1 2015 84

Osteoporosis-Pipeline by Pantarhei Bioscience BV, H1 2015 85

Osteoporosis-Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015 86

Osteoporosis-Pipeline by Pfizer Inc., H1 2015 87

Osteoporosis-Pipeline by PhytoHealth Corporation, H1 2015 88

Osteoporosis-Pipeline by PolyNovo Limited, H1 2015 89

Osteoporosis-Pipeline by R-Pharm, H1 2015 90

Osteoporosis-Pipeline by Radius Health, Inc., H1 2015 91

Osteoporosis-Pipeline by Richter Gedeon Nyrt., H1 2015 92

Osteoporosis-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 93

Osteoporosis-Pipeline by Shin Poong Pharm.Co., Ltd., H1 2015 94

Osteoporosis-Pipeline by STELIS Biopharma Pvt. Ltd., H1 2015 95

Osteoporosis-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 96

Osteoporosis-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 97

Osteoporosis-Pipeline by TAmiRNA GmbH, H1 2015 98

Osteoporosis-Pipeline by TSRL, Inc., H1 2015 99

Osteoporosis-Pipeline by Uni-Bio Science Group Ltd., H1 2015 100

Osteoporosis-Pipeline by Unigene Laboratories, Inc., H1 2015 101

Osteoporosis-Pipeline by Ventria Bioscience, H1 2015 102

Osteoporosis-Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H1 2015 103

Osteoporosis-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 104

Assessment by Monotherapy Products, H1 2015 105

Assessment by Combination Products, H1 2015 106

Number of Products by Stage and Target, H1 2015 108

Number of Products by Stage and Mechanism of Action, H1 2015 111

Number of Products by Stage and Route of Administration, H1 2015 114

Number of Products by Stage and Molecule Type, H1 2015 116

Osteoporosis Therapeutics-Recent Pipeline Updates, H1 2015 246

Osteoporosis-Dormant Projects, H1 2015 269

Osteoporosis-Dormant Projects (Contd..1), H1 2015 270

Osteoporosis-Dormant Projects (Contd..2), H1 2015 271

Osteoporosis-Dormant Projects (Contd..3), H1 2015 272

Osteoporosis-Dormant Projects (Contd..4), H1 2015 273

Osteoporosis-Dormant Projects (Contd..5), H1 2015 274

Osteoporosis-Dormant Projects (Contd..6), H1 2015 275

Osteoporosis-Dormant Projects (Contd..7), H1 2015 276

Osteoporosis-Dormant Projects (Contd..8), H1 2015 277

Osteoporosis-Discontinued Products, H1 2015 278

Osteoporosis-Discontinued Products (Contd..1), H1 2015 279

List of Figures

Number of Products under Development for Osteoporosis, H1 2015 20

Number of Products under Development for Osteoporosis-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 22

Number of Products under Investigation by Universities/Institutes, H1 2015 28

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Products, H1 2015 32

Assessment by Monotherapy Products, H1 2015 105

Number of Products by Top 10 Targets, H1 2015 107

Number of Products by Stage and Top 10 Targets, H1 2015 107

Number of Products by Top 10 Mechanism of Actions, H1 2015 110

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 110

Number of Products by Top 10 Routes of Administration, H1 2015 113

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 113

Number of Products by Top 10 Molecule Types, H1 2015 115

Number of Products by Stage and Top 10 Molecule Types, H1 2015 115

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abiogen Pharma S.p.A.

Ablynx NV

Alethia Biotherapeutics Inc.

Alize Pharma SAS

Alkem Laboratories Ltd.

Amgen Inc.

Amura Holdings Limited

Arcarios BV

Astellas Pharma Inc.

Bone Medical Limited

Bone Therapeutics SA

Caladrius Biosciences, Inc.

Chronos Therapeutics Limited

Chugai Pharmaceutical Co., Ltd.

Corium International, Inc.

Critical Pharmaceuticals Limited

Daiichi Sankyo Company, Limited

ElexoPharm GmbH

Eli Lilly and Company

EndoCeutics, Inc.

Ensoltek Co., Ltd.

Enzo Biochem, Inc.

F. Hoffmann-La Roche Ltd.

Galapagos NV

Glide Pharmaceutical Technologies Limited

Hanmi Pharmaceuticals, Co. Ltd.

Haoma Medica Ltd.

IMMD Inc.

Immunovo BV

Inbiopro Solutions Pvt. Ltd.

Kaken Pharmaceutical Co., Ltd.

Kolltan Pharmaceuticals, Inc.

Lead Discovery Center GmbH

Lupin Limited

Medivir AB

Merck & Co., Inc.

Merrion Pharmaceuticals Plc

Novartis AG

Omeros Corporation

Oncobiologics, Inc.

Oscotec Inc.

Osteologix Holdings Plc

Pantarhei Bioscience BV

Paras Biopharmaceuticals Finland Oy

Pfizer Inc.

PhytoHealth Corporation

PolyNovo Limited

R-Pharm

Radius Health, Inc.

Richter Gedeon Nyrt.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Shin Poong Pharm.Co., Ltd.

STELIS Biopharma Pvt. Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Takeda Pharmaceutical Company Limited

TAmiRNA GmbH

TSRL, Inc.

Uni-Bio Science Group Ltd.

Unigene Laboratories, Inc.

Ventria Bioscience

Wroclawskie Centrum Badan EIT+ Sp. z o.o.

Zydus Cadila Healthcare Limited

Osteoporosis Therapeutic Products under Development, Key Players in Osteoporosis Therapeutics, Osteoporosis Pipeline Overview, Osteoporosis Pipeline, Osteoporosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com